# ABSK061

Source: https://onco.cc/drugs/absk061/  
OnCo record `absk061` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ABSK061 is an experimental small-molecule drug from Abbisko Therapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, bladder & urothelial cancer and non-small-cell lung cancer, aimed at HER2 and FGFR2.

## Summary

ABSK061 is a small-molecule drug developed by Abbisko Therapeutics. Its targets are HER2 and FGFR2. ClinicalTrials.gov describes the intervention as: Participants with HER2-Gastric/Gastroesophageal Junction Cancer and fibroblast growth factor receptor 2( FGFR2 ) amplification and overexpression will receive a dose of ABSK061 + ABSK043 oral capsule in combination with CAPOX until disease. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer, bladder & urothelial cancer and non-small-cell lung cancer. The largest, NCT06632262, plans to enrol 202 participants with primary completion expected 2029-11-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule (structure undisclosed or not yet in PubChem)
- Mechanism: Small-molecule drug directed at HER2 and FGFR2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of ABSK061: https://clinicaltrials.gov/search?intr=ABSK061

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [FGFR2](https://onco.cc/targets/fgfr2/), [HER2](https://onco.cc/targets/her2/)
- companies: [Abbisko Therapeutics](https://onco.cc/companies/abbisko/)
- trials: [A Phase 2 Clinical Study of ABSK061 and ABSK043](https://onco.cc/trials/nct06632262/)

---
JSON: https://onco.cc/api/v1/entities/absk061.json